Kite enlists Epic Bio to apply epigenetic editing in creating next-gen CAR-T cells
Kite, the Gilead subsidiary specializing in CAR-T, is trying out epigenetic editing as it seeks new ways to create next-generation cell therapies that are more effective against cancer.
Teaming up with California-based Epic Bio, Kite will tap its new partner’s technology to engineer T cells by tinkering with gene expression — in hopes of “in essence, overcoming more than one tumor challenge with one technology,” said David Barrett, Kite’s vice president of cell biology and translational medicine.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.